

CURRICULUM VITAE

H. CODY MEISSNER, M.D.
CHIEF, PEDIATRIC INFECTIOUS DISEASE SERVICE
NEMC BOX #321

TUFTS MEDICAL CENTER
800 WASHINGTON STREET
BOSTON, MASSACHUSETTS 02111

Tel: (617) 636-5227

Fax: (617) 636-4300

E-mail: cmeissner@tuftsmedicalcenter.org

EDUCATION

1963 Browne & Nichols School
Cambridge, MA
1967 University of Vermont
Burlington, VT
1973 M.D., Tufts University School of Medicine
Boston, MA

POST GRADUATE TRAINING

1973 - 1975 Internship and Residency
Boston Floating Hospital
New England Medical Center
Boston, MA
1975 - 1977 Research Associate
Public Health Service
National Institute of Child Health and Human Development
National Institutes of Health
Bethesda, MD
1977 - 1978 Infectious Disease Fellow
Children's Hospital-Beth Israel-Dana Farber Cancer Center
Boston, MA
1978 - 1981 Post-Doctoral Fellow
Harvard Medical School
Department of Microbiology

LICENSURE AND CERTIFICATION

1973 Mass. State Medical License, #37426
1974 National Board of Medical Examiners
1981 American Board of Pediatrics
1994 Pediatric Infectious Disease Board Certification
2000 Pediatric Infectious Disease Board Re-Certification
2008 Pediatric Infectious Disease Board Re-Certification

ACADEMIC APPOINTMENTS

1972 - 1973 Research Associate
Stanford Medical Center
Palo Alto, California
1979 - 1988 Assistant Professor of Pediatrics
Tufts School of Medicine
1984 - 1988 Assistant Professor of Pathology
Tufts School of Medicine
1988 - 2006 Associate Professor of Pediatrics
Tufts School of Medicine
2006-present Professor of Pediatrics
Tufts University School of Medicine

HOSPITAL APPOINTMENTS

1978 - 1979 Pediatrician
Division of Infectious Disease
New England Medical Center

1984 - 1986 Assistant Pathologist
Department of Pathology
New England Medical Center

1985 - 1986 Director
Diagnostic Virology Laboratory
New England Medical Center

1989 - present Chief
Division of Pediatric Infectious Disease
New England Medical Center

2010 - 2013 Director of Pediatric Clinical Trials

2013 - 2015 Co-Director, Clinical and Translational Research Center (CTRC)
Tufts University School of Medicine

OTHER PROFESSIONAL POSITIONS

1983 - 1993 Infectious Disease Consultant
St. Margaret's Hospital (Neonatal Services), Boston, MA

1986 - 2001 Infectious Disease Consultant
New England Pediatric Care

1994 - 1998 Pediatric Infectious Disease Consultant
Newton-Wellesley Hospital
Newton, MA

1996 - 1999 Pediatric Infectious Disease Consultant
St. Elizabeth's Medical Center
Boston, MA

1999 - 2005 Committee on Infectious Disease (COID)
American Academy of Pediatrics (AAP)

1999 - 2000 Committee on Pediatric AIDS
American Academy of Pediatrics

2003 - 2005 Vice Chair, Committee on Infectious Disease
American Academy of Pediatrics

2007 - Present Consultant to Committee on Infectious Disease
American Academy of Pediatrics

2008 - Present Advisory Committee on Immunization Practices (ACIP)
Centers for Disease Control and Prevention (CDC)

2010 - Present Massachusetts Vaccine Purchasing Advisory Council

2017 - Present National Vaccine Advisory Committee, United States Department of Health and Human Services

2017 - Present Vaccine Injury Compensation Program, United States Department of Health and Human Services

AWARD

- Massachusetts 2017 Recipient of the CDC Childhood Immunization Award

ORIGINAL REPORTS

1. **Meissner HC**, Meyer J, Maizel JV, and Westphal H: Visualization and mapping of late nuclear adenovirus RNA. *Cell* 1977; 10:225-235.
2. **Meissner HC**, Smith AL: The current status of chloramphenicol. *Pediatrics* 1979; 64:348-356.
3. Wechsler SL, **Meissner HC**, Ray U, Weiner H, Rustigian R, Fields BN: Immune response in SSPE and multiple sclerosis: Antibody response to measles virus proteins. In Bishop DHL and Compans RW (eds.). *The Replication of Negative Strand Viruses*, Elsevier/North-Holland, New York, 1981, pp 615-622.
4. **Meissner HC**, Gellis SE, Melliken HF: Lyme disease presenting as aseptic meningitis. *Am J Dis Child* 1982; 136:465-467.
5. Wechsler SL and **Meissner HC**: Elevated antibody levels against measles virus P protein in sera of patients with multiple sclerosis. *Infect Immun* 1983; 40:1226-1229.
6. **Meissner HC**, Murray SA, Kiernan MA, Snyderman DR, McIntosh K: A simultaneous outbreak of respiratory syncytial virus and parainfluenza virus type 3 in a newborn nursery. *J Pediatr* 1984; 104:680-684.
7. Maguire JF and **Meissner HC**: Onset of encephalitis early in the course of varicella infection. *J Pediatr Infect Dis* 1985; 4:699-701.
8. Outwater KM, **Meissner HC**, Peterson MB: Ribavirin administration to infants receiving mechanical ventilation. *Am J Dis Child* 1988; 142:512-515.
9. Snyderman DR, Greer C, **Meissner HC**, McIntosh K: Prevention of nosocomial transmission of respiratory syncytial virus in a newborn nursery. *Infect Control Hosp Epidemiol* 1988; 9:105-108.
10. Fulton DR, **Meissner HC**, Peterson MB: Kawasaki disease: the effect of current therapy on eicosanoid metabolism. *Am J Cardiol* 1988; 61:1323-1327.
11. Shulman ST (ed), Bass JL, Bierman F, Burns JC, Chung K, Dillon MJ, Duffy E, Fulton D, Gersony WM, Gidding S, Gillespie SM, Glode MP, Koren G, Lehman TJA, Mason WH, **Meissner C**, Melish ME, Neches WH, Newburger JC, Rose V, Rowley AH, Silverman E, Takahashi M: Management of Kawasaki Disease: A consensus statement prepared by North American Participants of the Third International Kawasaki Disease Symposium. *Pediatr Infect Dis J* 1989; 8:663-665.
12. Fulton DR, **Meissner HC**, Peterson MB: Prostaglandins in Kawasaki disease. *Proceedings of the Third International Kawasaki Disease Symposium*, (ed) Kawasaki, T. Japan Heart Foundation, Tokyo 1989; 268-271.
13. Hillyer CD, Schwenn MR, Fulton DR, **Meissner HC**, Berkman EM: Autoimmune hemolytic anemia in Kawasaki disease: A case report. *Transfusion* 1990; 30:738-740.
14. **Meissner HC**, Pasternack MS: Case Records of the Massachusetts General Hospital. Case 43-1990. *N Engl J Med* 1990; 323:1189-99.
15. **Meissner C**, Reimer CB, Black C, Broome C, Rabson A, Siber GR, Delaney N, Connors M, Ambrosino DM: Interpretation of IgG subclass values: A comparison of two assays. *J Pediatr* 1990; 117:726-31.

ORIGINAL REPORTS

16. Burns JC, Mason WH, Glode MP, Shulman ST, Melish ME, **Meissner C**, Bastian J, Beiser AS, Meyerson HM, Newburger JW, for the U.S. Multicenter Kawasaki Disease Study Group: Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. *J Pediatr* 1991;118:680-6.
17. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, Mason WH, **Meissner HC**, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen FS: A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. *N Engl J Med* 1991; 324:1633-9.
18. Comenzo R, Malachowski M, **Meissner HC**, Fulton D, Berkman E: Immune hemolysis, disseminated intravascular coagulation and serum sickness following large dose intravenous immunoglobulin therapy for Kawasaki disease. *J Pediatr* 1992;120:926-928.
19. Hsu H, Moye J, Kunches L, Ng P, Shea B, Caldwell B, Tobin S, Willoughby A, McIntosh K, **Meissner HC**, Pasternack M, Pelton S, Stechenberg B, Sullivan J, Mofenson L, DeMaria A, Grady G: Perinatally acquired human immunodeficiency virus infection: extent of clinical recognition in a population-based cohort. *Pediatr Infect Dis J* 1992;11:941-945.
20. Abe J, Kotzin BL, **Meissner C**, Melish ME, Takahashi M, Fulton D, Romagne F, Malissen B, Leung DYM: Characterization of T cell repertoire changes in acute Kawasaki disease. *J Exp Med* 1993; 177:791-796.
21. **Meissner HC**, Fulton DR, Groothuis JR, Geggel RL, Marx GR, Hemming VG, Hougen T, Snyderman DR: Controlled trial to evaluate protection of high risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. *Antimicrob Agents and Chemother* 1993; 37:1655-1658.
22. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, **Meissner HC**, Fulton DR, Welliver RC, Tristram DA, Siber GR, Prince GA, Van Raden M, Hemming VG: Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. *N Engl J Med* 1993;329:1524-1530.
23. Leung DYM, **Meissner HC**, Fulton DR, Murray DL, Kotzin BL, Schlievert PM: Toxic shock syndrome toxin-secreting *Staphylococcus aureus* in Kawasaki syndrome. *Lancet* 1993;342:1385-1388.
24. **Meissner HC**: Economic impact of viral respiratory disease in children. *J Pediatr* 1994;124:S17-S21.
25. Huse DM, **Meissner HC**, Lacey MJ, Oster G: Childhood vaccination against chickenpox: an analysis of benefits and costs. *J Pediatr* 1994;124:869-874.
26. Guerina NG, Hsu HW, **Meissner HC**, Maquire JH, Lynfield R, Stechenberg B, Abrams I, Pasternack MS, Hoff R, Eaton RB, Grady GF and the New England Regional Toxoplasma Working Group: Neonatal serologic screening and early treatment for congenital *Toxoplasma gondii* infection. *N Engl J Med* 1994;330:1858-1863.
27. **Meissner HC**, Schlievert PM, Leung DYM: Mechanisms of immunoglobulin action: observations on Kawasaki syndrome and RSV prophylaxis. *Immun Rev* 1994;139:109-123.

ORIGINAL REPORTS

28. Snyderman R, Werner BG, **Meissner HC**, Cheeseman SH, Schwab J, Bednarek F, Kennedy JL, Herschel M, Magno A, Levin M, Valaes T, Berkman E, McIver J, Leszczynski J, Griffith J, Grady G: Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. *Pediatr Infect Dis J* 1995;14:34-40.
29. Groothuis JR, Simoes EAF, Hemming VG and the Respiratory Syncytial Virus Immune Globulin Study Group: Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). *Pediatrics* 1995;95:463-467.
30. Leung DYM, **Meissner HC**, Fulton DR, Quimby F, Schlievert PM: Superantigens in Kawasaki syndrome. *Clin Immunol and Immunopath* 1995;77:119-126.
31. Hay JW, Ernst RL, **Meissner HC**: Respiratory syncytial virus immune globulin: a cost effectiveness analysis. *Am J Managed Care* 1996;2:851-61.
32. **Meissner HC**, Chartrand SA, Fulton DR, Groothuis JR, Rodriguez WJ, Welliver RC: Prevention of Respiratory Syncytial Virus Infection in High-Risk Infants: Consensus Opinion on the role of Immunoprophylaxis with RSV Hyperimmune Globulin. *Pediatr Infect Dis J* 1996;15:1059-1068.
33. Rodriguez WH, Grueber WC, Welliver RC, Groothuis JR, Simoes EAF, **Meissner HC**, Hemming VG, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA, and the RSVIG Study Group. Respiratory syncytial virus immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections. *Pediatrics* 1997;99:454-461
34. **Meissner HC**, Groothuis JR: Immunoprophylaxis and the Control of RSV Disease. (Commentary). *Pediatrics* 1997;100:260-263.
35. Bloom BJ, Wyckoff PM, **Meissner HC**, Steere AC: Neurocognitive abnormalities in children following classic manifestations of Lyme disease. *Pediatr Infect Dis J* 1998;17:189-96.
36. Beiser AS, Takahashi MM, Baker AL, Sundel RP, Newburger JW for the US Multicenter Kawasaki Disease Study Group: A predictive instrument for coronary artery aneurysms in Kawasaki Disease. *American Journal of Cardiology* 1998;81:1116-1120.
37. The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from RSV infection in high-risk infants. *Pediatrics* 1998;102:531-537.
38. Simoes EAF, Sondheimer HM, Top FH, **Meissner HC**, Welliver RC, Kramer AA, Groothuis JR, and the Cardiac Study Group: Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. *Journal of Pediatrics* 1998;133:492-499.
39. Malley R, DeVincenzo J, Ramillo O, Dennehy PH, **Meissner HC**, Gruber WC, Sanchez PJ, Jahri H, Balsley J, Carlin D, Buckingham S, Vernacchio, Ambrosino DM: Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. *Journal of Infectious Disease* 1998;178:1555-61.
40. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP for the US/Canadian Kawasaki syndrome study group: Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. *Pediatr Infect Dis J* 1998;17:1144-1148.

ORIGINAL REPORTS

41. Barron KS, Shulman ST, Rowley A, Taubert K, Myones BL, **Meissner HC**, Peters J, Duffy CE, Silverman E, Sundel R: Report of the National Institutes of Health workshop on Kawasaki disease. *Journal of Rheumatology* 1999;26:170-190.
42. **Meissner HC**, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, Rodriguez WJ: Immunoprophylaxis with palivizumab, a humanized RSV monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: A consensus opinion. *Pediatr Infect Dis J*. 1999;18:223-231.
43. **Meissner HC**, Groothuis JR, Rodriguez WJ, Welliver RC, Hogg G, Gray PH, Loh R, Simoes EAF, Sly P, Miller AK, Nichols AI, Jorkasky DK, Everitt DE, Thompson KA: Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. *Antimicrob Agents & Chemother*. 1999;43:1183-1188.
44. Cunningham MW, **Meissner HC**, Heuser JS, Pietra BA, Kurahara DK, Leung DYM: Anti-human cardiac myosin autoantibodies in Kawasaki syndrome. *Journal of Immunology* 1999;163:1060-1065.
45. Malley R, Vernacchio L, DeVincenzo J, Ramilo O, Dennehy PH, **Meissner HC**, Gruber WC, Jafri H, Sanchez PJ, MacDonald K, Montana JB, Thompson CM, Ambrosino DM: Enzyme-linked immunosorbent assay to assess respiratory syncytial virus (RSV) concentration and correlate results with inflammatory mediators in tracheal secretions. *Pediatric Infectious Disease Journal* 2000;19:1-7.
46. **Meissner HC**, Leung DYM: Superantigens, conventional antigens and the etiology of Kawasaki syndrome. *Pediatric Infectious Disease Journal* 2000;19:91-94
47. Echevarria JE, Erdman DD, **Meissner HC**, Anderson L: Rapid molecular epidemiologic studies of human parainfluenza viruses based on direct sequencing of amplified DNA from a multiplex RT-PCR assay. *Journal of Virologic Methods* 2000;88:105-9.
48. Wang VJ, Kuppermann N, Malley R, Barnett ED, **Meissner HC**, Schmidt EV, Fleisher GR: Meningococcal disease among children in a large metropolitan area, 1981-1996. *Clinical Infectious Disease*. 2001;32:1004-1009
49. **Meissner HC**. Uncertainty in the management of viral lower respiratory tract disease. (Commentary) *Pediatrics* 2001;108:1000-1004
50. Leung DYM, **Meissner HC**, Shulman ST, Mason WH, Gerber MA, Glode MP, Myones BL, Wheeler JG, Ruthazer R, Schlievert PM. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. *J Pediatr* 2002;140:742-6
51. **Meissner HC**, Pickering LK. Control of disease attributable to *Haemophilus influenzae* type b and the National Immunization Program. (Commentary) *Pediatrics* 2002;110:820-823
52. **Meissner HC**. Selected populations at increased risk from respiratory syncytial virus infection. *Pediatr Infect Dis J* 2003;22:S40-5
53. **Meissner HC**, Leung DYM. Kawasaki syndrome: Where are the answers? (Commentary) *Pediatrics* 2003;113:672-676

ORIGINAL REPORTS

54. **Meissner HC**, Townsend T, Wenman W, Kaplan SL, Morfin MR, Edge-Padbury B, Naberhuis-Stenhouwer, Bruss JB. Hematologic effects of linezolid in young children. *Pediatr Infect Dis J* 2003;22:S186-192
55. Feltes TF, Cabalka AK, **Meissner HC**, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM & Cardiac Synagis study group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. *J Pediatr* 2003;143:532-540
56. **Meissner HC**, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Technical Report. *Pediatrics* 2003;112:1447-1452
57. **Meissner HC**, Rennels MB. Unpredictable patterns of viral respiratory disease in children. (Commentary) *Pediatrics* 2004;113:1814-1816
58. **Meissner HC**, Commentary: The unresolved issue of risk factors for hospitalization of infants with respiratory syncytial virus infection born after 33-35 weeks gestation. *Pediatr Infect Dis J* 2004;23:821-823
59. **Meissner HC**, Anderson LJ, Pickering LK. Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab. (Commentary) *Pediatrics* 2004;114:1082-1084
60. **Meissner HC**, Strebel PM, Orenstein WA. Measles vaccine and the potential for worldwide eradication of measles. *Pediatrics* 2004;114:1065-1069
61. Belshe BB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, **Meissner HC**, Madhi S, Robertson D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TT. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. *Journal of Infectious Disease* 2004;190:2096-2103
62. Shinefield H, Williams WR, Marchant C, Reisinger K, Stewart T, **Meissner HC**, Guerrero J, Klopfer SO, Schodel F, Kuter BJ. Dose response study of a quadravalent measles, mumps, rubella and varicella vaccine in healthy children. *Pediatr Infect Dis J* 2005;24:670-675
63. **Meissner HC**, Reef SE, Cochi S. Elimination of rubella from the United States: A milestone on the road to global elimination. (Commentary) *Pediatrics* 2006;117:933-935
64. Lieberthal AS, Bauchner H, Hall CB, Johnson DW, Kotagal U, Light MJ, Mason W, **Meissner HC**, Phelan, Zorc JJ. Diagnosis and management of bronchiolitis. Clinical practice guideline for the American Academy of Pediatrics. *Pediatrics* 2006;118:1774-1793
65. **Meissner HC**, Long SS. Respiratory syncytial virus infection and recurrent wheezing: A complex relationship. (Editorial) *Journal of Pediatrics* 2007;151:6-7
66. **Meissner HC**, DeVincenzo JP, editors. Supplement: Seasonal and geographic variation in respiratory syncytial virus outbreaks across the United States. *Pediatr Infectious Disease Journal* 2007;26 (No. 11)

ORIGINAL REPORTS

67. Marin M, **Meissner HC**, Seward JF. Varicella prevention in the United States: A review of successes and challenges. *Pediatrics* 2008;122:e744
68. **Meissner HC**, Bocchini JA, Brady MT, Hall CB, Kimberlin DW, Pickering LK. The role of immunoprophylaxis in the reduction of disease attributable to RSV (editorial). *Pediatrics* 2009;124:1676-1679
69. Comeau AM, Hale JE, Pai SY, Bonilla FA, Notarangelo LD, Pasternack MS, **Meissner HC**, Cooper ER, DeMaria A, Sahai I, Eaton RB. Guidelines for implementation of population-based newborn screening for severe combined immunodeficiency. *Journal of Inherited Metabolic Disease* 2010;33 (Suppl 2):S273-S281
70. Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, Brozanski BS, Palmer Kgh, Trautman MS, **Meissner HC**, Sasidharan P, Fretz J, Kokai-Kun JF, Kramer WG, Fischer GW, Mond JJ. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. *Pediatrics* 2011;128:271-279
71. Akinsanya-Beysolow I, Jenkins R, **Meissner HC**. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for persons aged 0 through 18 years—United States, 2013. *MMWR* 2013;62:2-8
72. Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, **Meissner HC**, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease, Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2013;62(2):1-28
73. **Meissner HC**, Kimberlin DW. RSV immunoprophylaxis: Does the benefit justify the cost? (editorial) *Pediatrics* 2013;132(5):915-18
74. Ralston SL, Lieberthal AS, **Meissner HC**, Alverson BK, Baley JE, Gadowski AM, Johnson DW, Light MJ, Maraqa NF, Mendonca EA, Phelan KJ, Zorc JJ, Stanko-Lopp D, Brown MA, Nathanson I, Rosenblum E, Sayles III S, Hernandez-Cancio S. Clinical Practice Guideline: The diagnosis, management and prevention of bronchiolitis. *Pediatrics* 2014;134:e1471-e1502
75. **Meissner HC**, Brady MT. Respiratory Syncytial virus: A Byzantine pathogen. *J Pediatrics* 2016;174(3):6-9
76. **Meissner HC**. Immunization policy and the importance of sustainable vaccine pricing. *Journal of the American Medical Association* 2016;315(10):981-982
77. Kim L, Abramson JS, Anderson LJ, Byington CL, Chen GL, DeVinchenzo J, Edwards KM, Englund JA, Falsey AR, Griffin MR, Karron RA, Martin KG, **Meissner HC**, Munoz FM, Pavia AT, Piedra PA, Schaffner W, Singleton R, Talbot HK, Walsh EE, Zucker JR, Gerber SI. Identifying gaps in RSV disease epidemiology in the United States prior to the introduction of vaccines. *Clinical Infectious Disease* 2017;65:1020-1025
78. Winterstein AG, Choi Y, **Meissner HC**. Association of age with risk of hospitalization for RSV in preterm infants with chronic lung disease. *JAMA Pediatrics* 2017;doi:10.1001/jamapediatrics.2017.3792

AMERICAN ACADEMY OF PEDIATRICS
STATEMENTS BY THE COMMITTEE ON INFECTIOUS DISEASE

1. Abramson JS, Baker C J, Fisher MC, Gerber MA, **Meissner HC**, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ, Peter G, Pickering LK, MacDonald N, Halsey N. Possible association of intussusception with rotavirus vaccination. *Pediatrics* 1999;104:575
2. Abramson JS, Baker C J, Fisher MC, Gerber MA, **Meissner HC**, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ. Recommended childhood immunization schedule-United States, January-December 2000. *Pediatrics* 2000;105:148-151
3. Abramson JS, Baker C J, Fisher MC, Gerber MA, **Meissner HC**, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ, Peter G, Pickering LK, MacDonald N. Infection Control in Physicians' offices. *Pediatrics* 2000;105:1361-1369
4. Abramson JS, Baker CJ, Fisher MC, Gerber MA, **Meissner HC**, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ, Peter G, Pickering LK, MacDonald N. Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis. *Pediatrics* 2000;106:362-366
5. Abramson JS, Baker CJ, Fisher MC, Gerber MA, **Meissner HC**, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ, Peter G, Pickering LK, MacDonald N. Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate and Polysaccharide Vaccines and Antibiotic Prophylaxis. *Pediatrics* 2000;106:367-376
6. Abramson JS, Baker CJ, Fisher MC, Gerber MA, **Meissner HC**, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ, Peter G, Pickering LK, MacDonald N. Transmissible Spongiform Encephalopathies: A Review for Pediatricians. *Pediatrics* 2000;106:1160-1165
7. Abramson JS, Baker CJ, Fisher MC, Gerber MA, **Meissner HC**, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ, Pickering LK. Precautions Regarding the Use of Aerosolized Antibiotics. *Pediatrics* 2000;106:e89-95
8. Abramson JS, Baker CJ, Fisher MC, Gerber MA, **Meissner HC**, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ, Pickering LK. Meningococcal Disease Prevention and Control Strategies for Practice-Based Physicians (Addendum: Recommendations for College Students). *Pediatrics* 2000;106:1500-1504
9. Abramson JS, Baker C J, Fisher MC, Gerber MA, **Meissner HC**, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ, Pickering LK. Recommended Childhood Immunization Schedule-United States, January-December 2001. *Pediatrics* 2001;107:202-213
10. Abramson JS, Baker CJ, Fisher MC, Gerber MA, **Meissner HC**, Murray DL Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner BL, Whitley RJ, Pickering LK. Prevention of Hepatitis B in Adolescents. *Pediatrics* 2001;108:1392
11. Abramson JS, Baker CJ, Fisher MC, Gerber MA, **Meissner HC**, Murray DL Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner BL. Recommended childhood immunization schedule—United States, 2002. *Pediatrics* 2002;109:163-163

AMERICAN ACADEMY OF PEDIATRICS
STATEMENTS BY THE COMMITTEE ON INFECTIOUS DISEASE

12. Abramson JS, Baker CJ, Baltimore, RS, Fisher MC, McMillan JA, **Meissner HC**, Overturf GD, Prober CG, Powell KR, Rennels MB, Saari TN, Weiner BL, Pickering LK. Smallpox Vaccine. *Pediatrics* 2002;110:841-84
13. Abramson JS, Baker CJ, Baltimore, RS, Fisher MC, McMillan JA, **Meissner HC**, Overturf GD, Prober CG, Powell KR, Rennels MB, Saari TN, Weiner BL, Pickering LK. Head lice. *Pediatrics* 2002;110:638-643
14. Abramson JS, Baker CJ, Baltimore, RS, Fisher MC, McMillan JA, **Meissner HC**, Overturf GD, Prober CG, Powell KR, Rennels MB, Saari TN, Weiner BL, Pickering LK. Reduction of the influenza burden in children. *Pediatrics* 2002;110:1246-1252
15. Abramson JS, Baker CJ, Baltimore, RS, Bocchini JA, Long SS, McMillan JA, **Meissner HC**, Powell KR, Prober CG, Rennels MB, Saari TN, Weiner BL, Pickering LK. Recommended childhood and adolescent immunization schedule-United States, 2003. *Pediatrics* 2003;111:212-216
16. Abramson JS, Baker CJ, Baltimore, RS, Bocchini JA, Long SS, McMillan JA, **Meissner HC**, Powell KR, Prober CG, Rennels MB, Saari TN, Weiner BL. Immunization of preterm and low birth weight infants. *Pediatrics* 2003;112:193-198
17. Abramson JS, Baker CJ, Baltimore, RS, Bocchini JA, Long SS, McMillan JA, **Meissner HC**, Powell KR, Prober CG, Rennels MB, Saari TN, Weiner BL. Policy Statement. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. *Pediatrics* 2003;112:1442-1446
18. Rennels MB, Baker CJ, Baltimore, RS, Bocchini JA, Dennehy PH, Frenck RW, Long SS, McMillan JA, **Meissner HC**, Powell KR, Rubin LG. Recommended childhood and adolescent immunization schedule—United States, January-June, 2004. *Pediatrics* 2004;113:142-147
19. Rennels MB, Baker CJ, Baltimore, RS, Bocchini JA, Dennehy PH, Frenck RW, Hall CB, Long SS, McMillan JA, **Meissner HC**, Powell KR, Rubin LG, Sarri TM. Recommended Childhood and adolescent immunization schedule—United States, July—December 2004. *Pediatrics* 2004;113:1448.
20. Rennels MB, Baker CJ, Baltimore, RS, Bocchini JA, Dennehy PH, Frenck RW, Hall CB, Long SS, McMillan JA, **Meissner HC**, Powell KR, Rubin LG, Sarri TM. Non-therapeutic use of antimicrobial agents in animal agriculture: Implications for pediatrics. *Pediatrics* 2004;114:862-868
21. Rennels MB, **Meissner HC**, Baker CJ, Baltimore, RS, Bocchini JA, Dennehy PH, Frenck RW, Hall CB, Long SS, McMillan JA, Powell KR, Rubin LG, Sarri TM. Recommendations for influenza immunization of children. *Pediatrics* 2004;113:1441-1447
22. Rennels MB, Baker CJ, Baltimore, RS, Bocchini JA, Bradley JS, Dennehy PH, Frenck RW, Hall CB, Long SS, McMillan JA, **Meissner HC**, Powell KR, Rubin LG. Recommended childhood and adolescent immunization schedule: United States, 2005. *Pediatrics* 2005;115:182-185

AMERICAN ACADEMY OF PEDIATRICS
STATEMENTS BY THE COMMITTEE ON INFECTIOUS DISEASE

23. Rennels MB, **Meissner HC**, Baker CJ, Baltimore, RS, Bocchini JA, Bradley JS, Dennehy PH, Frenck RW, Hall CB, Long SS, McMillan JA, Powell KR, Rubin LG. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. *Pediatrics* 2005;116:496-505
24. Rennels MB, **Meissner HC**, Baker CJ, Baltimore, RS, Bocchini JA, Dennehy PH, Frenck RW, Hall CB, Long SS, McMillan JA, Powell KR, Rubin LG, Saari TN. Chemical-Biological terrorism and its impact on children. *Pediatrics* 2006;118:1267-1278
25. Rennels MB, **Meissner HC**, Baker CJ, Baltimore, RS, Bocchini JA, Bradley JS, Dennehy PH, Frenck RW, Hall CB, Long SS, McMillan JA, Powell KR, Rubin LG, Saari TN. The use of systemic fluoroquinolones. *Pediatrics* 2006;118:1287-1292

PUBLICATIONS AS A CONSULTANT & RED BOOK ASSOCIATE EDITOR TO THE AAP
COMMITTEE ON INFECTIOUS DISEASE

1. Prevention of influenza: Recommendations for influenza immunization of children, 2007-2008. *Pediatrics* 2008;121:e1016
2. Exposure to nontraditional pets at home and to animals in public settings: Risks to children. *Pediatrics* 2008;122:876-886
3. Prevention of influenza: Recommendations for influenza immunization of children, 2008-2009. *Pediatrics* 2008;122:1135-1141
4. Recommended childhood and adolescent immunization schedules-United States 2009. *Pediatrics* 2009;123:189-190
5. Drinking water from private wells and risks to children. *Pediatrics* 2009;123:1599-1605
6. Prevention of rotavirus disease: Updated guidelines for use of rotavirus vaccine. *Pediatrics* 2009;123:1412-1420
7. Policy statement-Recommendations for the prevention and treatment of influenza in children, 2009-2010. *Pediatrics* 2009;124:1216-1226
8. *Policy statement-Modified recommendations for use of palivizumab for prevention of RSV infections. *Pediatrics* 2009;124:1694-1701
9. Policy statement-Recommended childhood and adolescent immunization schedules-United States 2010. *Pediatrics* 2010;125:195-196
10. Policy Statement—Recommendations for the prevention of Streptococcal pneumoniae infections in infants and children: Use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). *Pediatrics* 2010;126:186-190
11. Clinical Report—Head Lice. *Pediatrics* 2010;126:392-403
12. Policy Statement—Cochlear implants in children: Surgical site infections and prevention and treatment of acute otitis media and meningitis. *Pediatrics* 2010;126:381-391
13. Policy Statement—Recommendation for mandatory influenza immunization of all health care personnel. *Pediatrics* 2010;126:809-815

**PUBLICATIONS AS A CONSULTANT/RED BOOK ASSOCIATE EDITOR TO THE AAP
COMMITTEE ON INFECTIOUS DISEASE**

14. Policy Statement—Recommendations for prevention and control of influenza in children, 2010-2011. *Pediatrics* 2010;126:816-826
15. *Policy Statement—Recommended childhood and adolescent immunization schedules—United States, 2011. *Pediatrics* 2011;127:387-388
16. Policy Statement—Rabies prevention policy update: New reduced-dose schedule. *Pediatrics* 2011;127:785-787
17. Policy Statement—Recommendations for the prevention of perinatal group B Streptococcal disease. *Pediatrics* 2011;128:611-616
18. Policy Statement—Prevention of varicella: Update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. *Pediatrics* 2011;128:630-632
19. Recommendations for administering hepatitis A vaccine to contacts of international adoptees. *Pediatrics* 2011;128:803-804
20. Poliovirus. *Pediatrics* 2011;128:805-808
21. Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid and acellular pertussis vaccine (Tdap). *Pediatrics* 2011;128:809-812
22. Recommendations for prevention and control of influenza in children, 2011-2012. *Pediatrics* 2011;128:813-825
23. Meningococcal conjugate vaccines policy update: Booster dose recommendations. *Pediatrics* 2011;128:1213-1218
24. Immunizing parents and other close family contacts in the pediatric office setting. *Pediatrics* 2012;129:e247-e253
25. *Policy Statement—Recommended childhood and adolescent immunization schedules—United States, *Pediatrics* 2012. 2012;129:385-386
26. Policy Statement—HPV vaccine recommendations. *Pediatrics* 2012;129:602-605
27. Clinical Report—Epidemiology and diagnosis of health care—associated infections in the NICU. *Pediatrics* 2012;129(4):e1104-e1109
28. Policy Statement—Recommendations for prevention and control of influenza in children 2012-2013. *Pediatrics* 2012;130:780-792
29. Policy Statement—*Clostridium difficile* infection in infants and children. *Pediatrics* 2013;131:196-200
30. *Policy Statement—Recommended childhood and adolescent immunization schedule—United States, 2013 *Pediatrics* 2013;131:397-403
31. Clinical Report—Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. *Pediatrics* 2013;131:e635-e646

**PUBLICATIONS AS A CONSULTANT/RED BOOK ASSOCIATE EDITOR TO THE AAP
COMMITTEE ON INFECTIOUS DISEASE**

32. *Policy Statement—Recommended childhood and adolescent immunization schedules—United States, Pediatrics 2013;131:397-403
33. Clinical report—Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics 2013;131:e635-e646
34. Policy Statement—Recommendations for Prevention and control of influenza in children, 2013-2014 Pediatrics 2013;132:1-16
35. Clinical Report—Principles of judicious antibiotic prescribing for upper respiratory tract infections in pediatrics. Pediatrics 2013;132(11):1146-1154
36. *Policy Statement—Recommended childhood and adolescent immunization schedules—United States—2014. Pediatrics 2014;133(2):357-358
37. *Technical Report—Updated Guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for RSV infection. Pediatrics 2014;134(2):e620-638
38. *Policy Statement—Updated Guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for RSV infection. Pediatrics 2014;134(2):415-420
39. Policy Statement—Updated recommendations on the use of meningococcal vaccines. Pediatrics 2013;134(2):400-403
40. Policy Statement—Recommendations for prevention and control of influenza in children, 2014-2015. Pediatrics 2014;134(5):1-17
41. Technical Report—Interferon- γ release assays for diagnosis of tuberculosis infection and disease in children. Pediatrics 2014;134(6):e1763-e1773
42. Policy Statement—Immunization for Streptococcus pneumonia infections in high-risk children. Pediatrics 2014;134(6):1230-1233
43. Clinical Report—Eradicating polio: how the world's pediatricians can help stop this crippling illness forever. Pediatrics 2015;135(1):196-202
44. Policy Statement—Recommendations for Prevention and control of influenza in children, 2015-2016. Pediatrics 2015;136(4):792-808
45. *Policy Statement—Recommended childhood and adolescent immunization schedule—United States, 2016. Pediatrics 2016;137(3) originally published online Feb 1, 2016
46. Clinical Report—Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics 2016;138(2):e1-e21
47. Clinical Report—Parental presence during treatment of Ebola or other highly consequential infection. Pediatrics 2016;138(3):e20161891
48. Policy Statement—Recommendations for serogroup B meningococcal vaccine for persons 10 years and older. Pediatrics 2016;138(3):e20161890
49. Clinical Report—Countering vaccine hesitancy. Pediatrics 2016;138(3):e20162146

PUBLICATIONS AS A CONSULTANT/RED BOOK ASSOCIATE EDITOR TO THE AAP COMMITTEE ON INFECTIOUS DISEASE

50. Clinical Report—The use of systemic and topical fluoroquinolones. *Pediatrics* 2016;138(5):e20162706
51. Policy Statement—Medical versus nonmedical immunization exemptions for child care and school attendance. *Pediatrics* 2016;138(3):e20162145
52. Technical Report—Diagnosis, treatment and prevention of congenital toxoplasmosis in the United States. *Pediatrics* 2017;139(2):e20163860
53. Clinical Report—The need to optimize adolescent immunization. *Pediatrics* 2017;139(3):e20164186
54. Clinical Report—Practical approaches to optimize adolescent immunization. *Pediatrics* 2017;139(3):e20164187
55. *Policy Statement—Recommended childhood and adolescent immunization schedule—United States, 2017. *Pediatrics* 2017;139(3):e20164007
56. Policy Statement—Recommendations for prevention and control of influenza in children, 2017-2018. *Pediatrics* 2017;140(4):e20172550
57. Clinical Report—Infectious diseases associated with organized sports and outbreak control. *Pediatrics* 2017;140(4):e20172477
58. Policy Statement—Infection Prevention and Control in Pediatric Ambulatory Settings. *Pediatrics* 2017;140(5):e20172857
59. *Policy Statement—Recommended childhood and adolescent immunization schedule: United States, 2018. *Pediatrics* 2018;141(3):e20180083

*Meissner, HC primary author

PUBLICATIONS FROM THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES CENTERS FOR DISEASE CONTROL AND PREVENTION

1. Morse D, Pickering L, Baker C, Beck R, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Lett S, Marcy M, **Meissner C**, Neuzil K, Sawyer M, Sumaya C, Tempte J. Prevention and control of seasonal influenza with vaccines. *MMWR* 2009;58:RR-8
2. Morse D, Pickering L, Baker C, Beck R, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Lett S, Marcy M, **Meissner C**, Neuzil K, Sawyer M, Sumaya C, Tempte J. Use of influenza A(H1N1)2009 monovalent vaccine. *MMWR* 2009;58:RR-10
3. Morse D, Pickering L, Baker C, Beck R, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Lett S, Marcy M, **Meissner C**, Neuzil K, Sawyer M, Sumaya C, Tempte J. Japanese Encephalitis Vaccines. *MMWR* 2010;59:RR-1
4. Morse D, Pickering L, Baker C, Beck R, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Lett S, Marcy M, **Meissner C**, Neuzil K, Sawyer M, Sumaya C, Tempte J. Use of reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies. *MMWR* 2010;59:RR-2

**PUBLICATIONS FROM THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
CENTERS FOR DISEASE CONTROL AND PREVENTION**

5. Morse D, Pickering L, Baker C, Beck R, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Lett S, Marcy M, **Meissner C**, Neuzil K, Sawyer M, Sumaya C, Temple J. The use of combination measles, mumps, rubella and varicella vaccine. *MMWR* 2010;59:RR-3
6. Morse D, Pickering L, Baker C, Beck R, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Lett S, Marcy M, **Meissner C**, Neuzil K, Sawyer M, Sumaya C, Temple J. Use of anthrax vaccine in the United States. *MMWR* 2010;59:RR-6
7. Baker C, Pickering L, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Keitel W, Lett S, Marcy M, **Meissner C**, Neuzil K, Rosenbaum S, Sawyer M, Sumaya C, Temple J. Yellow Fever Vaccine. *MMWR* 2010;59:RR-7
8. Baker C, Pickering L, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Keitel W, Lett S, Marcy M, **Meissner C**, Neuzil K, Rosenbaum S, Sawyer M, Sumaya C, Temple J. Prevention and control of influenza with vaccines, 2010. *MMWR* 2010;59:RR-8
9. Baker C, Pickering L, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Keitel W, Lett S, Marcy M, **Meissner C**, Neuzil K, Rosenbaum S, Sawyer M, Sumaya C, Temple J. Antiviral agents for the treatment and chemoprophylaxis of influenza. *MMWR* 2011;60:RR-1.
10. Baker C, Pickering L, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Keitel W, Lett S, Marcy M, **Meissner C**, Neuzil K, Sawyer M, Sumaya C, Temple J. General Recommendations on Immunization. *MMWR* 2011;60:RR-2
11. Baker C, Pickering L, Chilton L, Cieslak P, Coyne-Beasley T, Duchin J, Ehresmann K, Englund J, Jenkins R, Judson F, Keitel W, Marcy M, **Meissner C**, Neuzil K, Rosenbaum S, Sawyer M, Temple J. Immunization of health-care personnel. *MMWR* 2011;60:RR-7

REVIEWS

1. Wechsler SL and **Meissner HC**: Measles and SSPE viruses: similarities and differences. *Prog Med Virol* 1982;28:65-95.
2. **Meissner HC**: Herpes simplex virus infection in the newborn. *Clin Dermatol* 1984; 2:23-28.
3. Olney LA and **Meissner HC**: Reye syndrome: Current management strategies. *Drug Therapy* 1984; 9:17-26.
4. Olney LA and **Meissner HC**: Consequences of varicella-zoster infection: Advances in treatment and prevention. *Clin Dermatol* 1989; 7:49-55.
5. **Meissner HC**: Management of Lyme disease. *Pediatr Infect Dis J* 1990; 9:601.
6. **Meissner C**: Role of laboratory tests in the diagnosis of Lyme disease. *Report on Pediatr Infect Dis* 1991; 2:1.
7. Lee MA, **Meissner HC**: Hepatitis in adolescents. *Adolescent Medicine: State of the Art Reviews*; Philadelphia, Hanley & Belfus, 1991; 2:499-507.
8. **Meissner HC**: Lyme disease. In Peter G, ed. *1991 Red Book: Report of the Committee on Infectious Diseases*. 22nd ed. Elk Grove Village, IL, American Academy of Pediatrics.

REVIEWS

9. **Meissner C**, Marx G, Geggel R, Fulton D: A retrospective comparison of two intravenous immune globulin products for single-dose treatment of Kawasaki disease. pp. 477-478: in Takahashi M and Taubert K (eds): *Proceedings of the Fourth International Symposium on Kawasaki Disease*, American Heart Association, Dallas, 1993.
10. **Meissner HC**: Respiratory syncytial virus and nosocomial disease. *Neonatal Intensive Care* 1994; 7:54-59.
11. Glode MP, **Meissner C**, Melish ME: Kawasaki syndrome: in Metz K (ed): *Pediatric UPDATE*, vol. 15, American Academy of Pediatrics, 1994.
12. **Meissner HC**: Prophylaxis and treatment of respiratory syncytial virus infection in high-risk infants: in Frantz ID (ed): *Neonatal Respiratory Diseases*, vol. 4, 1994.
13. **Meissner HC**, Leung DYM: Kawasaki syndrome. *Current Opinion in Rheumatology* 1995; 7:455-458
14. **Meissner HC**, Leung DYM: Immunoglobulin Therapy in Kawasaki Syndrome and RSV Prophylaxis. *Frontiers in Bioscience* 1, e55-64, 1 August 1996.
15. **Meissner HC**: Varicella vaccine: The first licensed herpes vaccine. *Infect Dis Clin Pract* 1996;5:424-427.
16. Leung DYM, **Meissner HC**, Schlievert P: The etiology and pathogenesis of Kawasaki Disease-how close are we to an answer? *Current Opinion in Infectious Disease* 1997;10:226-232.
17. Moskowitz H, **Meissner HC**: Tick-borne diseases: Warm weather worry. *Contemporary Pediatrics* 1997;14:33-49.
18. Leung DM, Schlievert PM, **Meissner HC**: The immunopathogenesis and management of Kawasaki syndrome. *Arthritis & Rheumatism* 1998;41:1538-47
19. American Academy of Pediatrics, Committee on Infectious Disease. Prevention of respiratory syncytial virus infection: Indications for the use of palivizumab and update on the use of RSV-IGIV. *Pediatrics* 1998;102:1211.
20. **Meissner, HC**: A novel approach to RSV prevention. *Infections in Medicine* 1999;16C:20-23.
21. Carbonell-Estrany X, Giuffre L, Kimpen JLL, Adam D, Valerius NH, Devlieger H, Shaw B, Muller W, Ruuskanen O, Cunha O, **Meissner HC**. Guidelines for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of RSV disease in high-risk infants: a consensus opinion. *Infections in Medicine* 1999;16, supplement G: 29-33
22. Leung DYM, **Meissner HC**: The many faces of Kawasaki syndrome. *Hospital Practice* 2000;35:77-94.
23. Dougherty NN, **Meissner HC**: Respiratory syncytial virus immunoprophylaxis: Impact on epidemiology. *Paediatr Drugs* 2000;2:127-132.
24. **Meissner HC**. Antiviral drugs for prophylaxis and treatment of influenza. *Pediatr. Inf. Dis. J.* 2001;20:1165-1167

REVIEWS

25. **Meissner HC.** Influenza: Emerging control of an old disease. *Pediatr Emergency Care* 2001;17:465-473.
26. Rennels MB, **Meissner HC.** Reduction of the influenza burden in children. *Pediatrics* 2002;110:e80
27. **Meissner HC.** Reducing the impact of viral respiratory infections in children. p 695-710 in Prober CG (ed) *Pediatric Clinics of North America*, Pediatric Infectious Diseases. Philadelphia. Elsevier, Inc. Vol 52;2005
28. **Meissner HC.** Eliminating indigenous transmission of hepatitis A: The crucial role of the recommendations of the advisory committee on immunization practices. *Contemporary Pediatrics (Supplement)* 2006;23:1-8
29. **Meissner HC.** Influenza vaccines: a pediatric perspective. *Current Opinion in Pediatrics* 2007;19:58-63
30. **Meissner HC.** Viral bronchiolitis in children. *N Engl J Med.* 2016 Jan 7;374(1):62-72. doi: 10.1056/NEJMra1413456.

LETTERS TO THE EDITOR

1. Miller K, Gouveia WA, Barza M, Bower K, Curtis L, Decker EL, Dorkin H, Estes M, Mackey W, Marchein D, **Meissner HC**, Miller R: Undesirable marketing practices in the pharmaceutical industry. *N Engl J Med* 1985; 313:54.
2. **Meissner HC:** Universal vaccination against varicella. *N Engl J Med* 1998;338:682.
3. **Meissner HC**, Leung DL: Kawasaki syndrome. *Pediatr Infect Dis J* 1999;18 (Jan) yellow pages.
4. **Meissner HC**, Rennels MB, Long SS, Pickering LK. Immunoprophylaxis with RespiGam. *Pediatrics* 2004;113:629
5. **Meissner HC**, Rennels MB, Pickering LK, Hall CB. Risk of severe respiratory syncytial virus disease, identification of high-risk infants and recommendations for prophylaxis with palivizumab. *Pediatr Infect Dis J* 2004;23:284-285
6. **Meissner HC**, Kimberlin DW. Clarifying costs and benefits of RSV immunoprophylaxis. *Pediatrics* 2014;133(4):e1101-e1103
7. **Meissner HC**, Brady MT, Byington CL, Kimberlin DW, Liberthal AS, Maldonado YA, Ralston SL, Winterstein A. Response to letter from Ambrose. *Pediatrics* 2014;134(6):e1782-e1784
8. **Meissner HC.** Viral bronchiolitis in children. *N Eng J Med* 2016;374(18):1793-1794
9. **Meissner HC.** Vaccine pricing and United States immunization policies. *JAMA* 2016;316(2):226-227

BOOK CHAPTERS

1. **Meissner HC**, Tularemia, p. 561. in Gellis SS and Kagan BM (eds): *Current Pediatric Therapy*, 9th edition, Philadelphia, W.B. Saunders, 1980.; Measles, p. 558, *Current Pediatric Therapy*, 10th edition 1982.; Measles, p. 563, Lyme Disease p. 578, Aseptic Meningitis p. 585, *Current Pediatric Therapy*, 11th edition, 1984.
2. Wechsler SL and **Meissner HC**: Subacute sclerosing panencephalitis and the eye. p. 251-261: in Darrell RW (ed): *Viral Diseases of the Eye*. Philadelphia, Lea and Febiger, 1985.
3. **Meissner HC**: Introduction to the viruses; the retroviruses and AIDS; polio and other enteroviruses; congenital and neonatal infections; zoonoses, in Schaechter M, Medoff Schlessinger D (eds): *Mechanisms of Microbial Disease*. Baltimore, Williams & Wilkins Co, 1989.
4. **Meissner HC**, Antiviral agents. p. 141-148: in Theoharides, TC (ed): *Pharmacology*; 1st edition. Boston, Little, Brown and Company, 1992.
5. **Meissner HC** and Storch GA: Picornaviruses: polio, other enteroviruses and the rhinoviruses, p. 407-419; **Meissner HC**: Arthropod-borne viruses, p. 420-424; **Meissner HC**: Rotaviruses and other viral agents of gastroenteritis, p. 459-465; **Meissner HC** and Coffin JM: Human retroviruses: AIDS and other diseases, p. 466-483, in Schaechter M, Medoff G, Eisenstein BI (eds): *Mechanisms of Microbial Disease*; 2nd edition. Baltimore, Williams & Wilkins Co., 1993.
6. Loutit JS, Theoharides TC, **Meissner HC**, Kisliuk RL, Keusch GT, Gorbach SL: Antimicrobial chemotherapy, p. 287-340: in Theoharides TC (ed): *Essentials of Pharmacology*; 2nd edition. Boston, Little, Brown and Company, 1996.
7. **Meissner HC** and Leung DYM: Kawasaki Syndrome, in Gorbach SL, Bartlett JG, Blacklow NR (eds): *Infectious Diseases*; 2nd edition. Philadelphia, W.B. Saunders Co., 1997.
8. **Meissner HC** and Storch GA: Picornaviruses: Polio viruses, other enteroviruses, and the rhinoviruses, p. 305-314; **Meissner HC**: Arthropod-borne viruses, p. 315-320; **Meissner HC**: Rotaviruses and other viral agents of gastroenteritis, p. 345-349; **Meissner HC** and Coffin JM: The human retroviruses: AIDS and other diseases, p. 350-365 in Schaechter M, Engleberg NC, Eisenstein BI, Medoff G (eds): *Mechanisms of Microbial Disease*; 3rd edition. Baltimore, Williams & Wilkins Co. 1998.
9. American Academy of Pediatrics. Pickering LK, ed. *2000 Red Book: Report of the Committee on Infectious Disease*, 25th ed. Elk Grove Village, IL
10. **Meissner HC** and Leung DYM. Kawasaki syndrome, p. 369-374; in Baddour L, Gorbach SL (eds) *Therapy of Infectious Disease*; 1st edition. Philadelphia, W. B. Saunders Co., 2003
11. **Meissner HC**. Kawasaki Syndrome. P. 479-483; in Johnson LR (ed) *Encyclopedia of Gastroenterology*; Elsevier, Inc. San Diego, CA, 2004
12. Leung DYM, **Meissner HC**. Kawasaki syndrome. p. 235-238; in Lichtenstein LM, Busse WW, Geha RS (eds) *Current Therapy in Allergy, Immunology, and Rheumatology*; 6th edition. Philadelphia, PA, Mosby, 2004
13. **Meissner HC** and Leung DYM. Kawasaki Syndrome, p. 1551-1556; in Gorbach SL, Bartlett JG, Blacklow NR (eds) *Infectious Disease*; 3rd Edition. Philadelphia, PA. Lippincott, Williams & Wilkins. 2004

BOOK CHAPTERS

14. Shelov SP, Hannemann RE, Agran PF, Altmann TR, Baker SS, Coleman WL, Dworkin PH, **Meissner HC**, Shapiro HL (eds): *Caring for your baby and young child, birth to age 5; 4th Edition*, Random House, American Academy of Pediatrics. 2004
15. **Meissner HC**. Perinatal Infections, p. 303-349 in Lockwood CJ, Lemons JA (eds): *Guidelines for Perinatal Care. 6th Edition*. American Academy of Pediatrics & The American College of Obstetricians and Gynecologists. Elk Grove Village, IL. 2007
16. Leung DYM, **Meissner HC**, Lucky AW. Kawasaki Syndrome. p 1626-1633; in Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ (eds): *Fitzpatrick's Dermatology in General Medicine. 7th Edition*. New York, NY. McGraw Hill. 2007
17. **Meissner HC**. Bronchiolitis. p 241-245; in Long SS, Pickering LK, Prober CG (eds): *Principles and Practice of Pediatric Infectious Diseases 3rd Edition*. Philadelphia, PA. Churchill Livingstone. 2008
18. **Meissner HC**. Rubella. p 624-627; in Heggenhougen, Quah (eds): International Encyclopedia of Public Health. Volume 5, Academic Press, San Diego. 2008
19. **Meissner HC**. Lyme disease. p 2249-2252; in McInerney TK, Adam HM, Campbell DE, Kamat DM, Kelleher KJ, (eds): Textbook of Pediatric Care. Elk Grove Village, IL: American Academy of Pediatrics; 2009
20. Shelov SP, Agran PF, Dworkin PH, Garner A, Greer F, Jana, L, **Meissner HC**, Milteer R. (eds): *Caring for your baby and young child, birth to age 5; 5th Edition*, Random House, American Academy of Pediatrics. 2009
21. **Meissner HC**. Passive Immunization. p 37-43; in Long SA, Pickering LK, Prober CG (eds): Principles and practice of Pediatric Infectious Diseases 4th Edition. Edinburgh, Elsevier Saunders. 2012
22. **Meissner HC**. Bronchiolitis. p 231-234; in Long SA, Pickering LK, Prober CG (eds): Principles and practice of Pediatric Infectious Diseases 4th Edition. Edinburgh, Elsevier Saunders. 2012
23. **Meissner HC**. Respiratory syncytial virus. p 1130-1135; in Long SA, Pickering LK, Prober CG (eds): Principles and Practice of Pediatric Infectious Diseases 4th Edition. Edinburgh, Elsevier Saunders. 2012
24. **Meissner HC**, Hall CB. Respiratory Syncytial Virus. p 2407-2434; in Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ (eds): Feigin & Cherry's Textbook of Pediatric Infectious Diseases. 7th Edition. 2014. Elsevier Saunders. Philadelphia, PA 2013
25. **Meissner HC**. Lyme disease. p 2338-2341; in McInerney TK (ed): Textbook of Pediatric Care. 2nd Edition. 2016. American Academy of Pediatrics, Elk Grove Village, IL
26. Goddard AF, **Meissner HC** Passive Immunization. p 37-43 in Long SA, Prober GC, Fischer M (eds): Principles and Practice of Pediatric Infectious Diseases 5th Edition. Philadelphia, Elsevier. 2018
27. **Meissner HC**. Respiratory Syncytial Virus. p 225-226 in Long SA, Prober GC, Fischer M (eds): Principles and Practice of Pediatric Infectious Diseases 5th Edition. Philadelphia, Elsevier. 2018
28. **Meissner HC** Bronchiolitis. p 234-238 in Long SA, Prober GC, Fischer M (eds): Principles and Practice of Pediatric Infectious Diseases 5th Edition. Philadelphia, Elsevier. 2018

PUBLISHED ABSTRACTS

1. **Meissner C**, Fields BN: Isolation and characterization of measles RNA. Replication of Negative Strand Viruses, St. Thomas, October 1980.
2. **Meissner HC**, Murray SA, Kiernan MA, Snyderman DR, McIntosh K: A simultaneous outbreak of respiratory syncytial virus (RSV) and parainfluenza virus type III (PI) in a newborn nursery. 22nd Interscience Conference of Antimicrobial Agents and Chemotherapy, Miami Beach, Florida October 1982.
3. **Meissner HC**, Rogers JA, Ho JL, Mulks M, Worthington M, Martin WJ: Antisera to *Neisseria meningitidis* group B cross-reacts on counter immunoelectrophoresis (CIE) with a *Neisseria perflava* from a septic patient. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, Nevada, October 1983.
4. Fulton DR, **Meissner HC**, Peterson MB: Plasma prostacyclin and thromboxane activity in acute Kawasaki disease: Markers for disease activity and therapeutic efficacy. Northeast Pediatric Cardiology Society, 4th Annual Meeting, Newport, Rhode Island, September 1986.
5. **Meissner C**, Fulton D, Sanderlin K, Pellett P: Human herpes virus-6 and the etiology of Kawasaki disease. The Third International Kawasaki Disease Symposium, Tokyo, Japan, December 1988.
6. Szer IS, **Meissner C**, Taylor E, Schaller JG, Steere AC: Natural history of Lyme arthritis in children: A ten-year perspective. American College of Rheumatology, 24th Annual Meeting, Cincinnati, Ohio, June 1989.
7. Connors M, Rabson A, **Meissner C**: Prevalence of complement and serum immunoglobulin deficiencies in children with first time meningococcal disease. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, September 1989.
8. **Meissner C**, Glass R, Kennedy J, Testa S, Magno A, Ryder R: A randomized, double blind study to evaluate protection against rotavirus infection conferred by oral gamma globulin. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, September 1989.
9. **Meissner C**, Szer IS, Zemel L, Taylor E, Steere AC: Penicillin or amoxicillin therapy for Lyme arthritis in children: Experience from 3 institutions. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, September 1989.
10. Newburger JW, (U.S. Multicenter Kawasaki Study Group): Preliminary results of multicenter trial on IVGG treatment of Kawasaki disease with single-infusion vs. four-infusion regimen. Society for Pediatric Research, Los Angeles, California May 1990.
11. Hsu, HW, Kunches L, Ng P, Moye J, Makarewicz L, Shea B, Grady G, Hoff R, McIntosh K, **Meissner C**, Pelton S, Sullivan J, Stechenberg B, and the Massachusetts Working Group on Surveillance of HIV in Children: Extent of recognition of perinatal HIV infection. 6th International Conference on AIDS, San Francisco, California, June 1990.
12. **Meissner C**, Szer I, Zemel L, Taylor E, Steere A: A comparison of amoxicillin and penicillin therapy for Lyme arthritis in children: Results from 3 hospitals. IV International Conference on Lyme Borreliosis, Stockholm, Sweden, June 1990.

PUBLISHED ABSTRACTS

13. Burns JC, Mason WH, Glode MP, Shulman ST, Melish ME, **Meissner C**, Bastion J, Beiser AS, Meyerson HM, Newburger JW, (U.S. Multicenter Kawasaki Disease Study Group): Clinical and laboratory characteristics of patients referred for evaluation of possible Kawasaki disease. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 1990.
14. Burns JC, Mason WH, Glode MP, Shulman ST, Melish ME, **Meissner C**, Bastion J, Beiser AS, Meyerson HM, Newburger JW, (U.S. Multicenter Kawasaki Disease Study Group): Epidemiological characteristics of patients referred for evaluation of possible Kawasaki disease. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 1990.
15. Hsu, H, Kunches L, Ng P, Moye J, Makarewicz L, Shea B, Grady G, Hoff R, McIntosh K, **Meissner C**, Pelton S, Sullivan J, Stechenberg B, (Working Group on Surveillance of HIV in Children): Pneumocystis carinii pneumonia in infants with human immunodeficiency virus infection. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 1990.
16. Snyderman DR, Werner BG, **Meissner HC**, Schwab J, Zaleski A, and The Neonatal CMVIG Study Group: Use of cytomegalovirus immune globulin in multiply transfused premature neonates. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 1990.
17. Hsu H, Moye J, Ng P, Shea B, Mofenson L, Kunches L, Tobin S, DeMaria A, Grady G, McIntosh K, **Meissner HC**, Pasternack M, Pelton S, Stechenberg B, Sullivan J, (Working Group on Surveillance of HIV in Children): Pneumococcal bacteremia in children with HIV infection. 7th International Conference on AIDS, Florence, Italy, June 1991.
18. **Meissner HC**, Fulton DR: A retrospective comparison of two intravenous gamma globulin products for the therapy of Kawasaki syndrome. 17th International Congress of Chemotherapy, Berlin, Germany, June 1991.
19. Burns JC, and the KD Multicenter Hearing Loss Study Group: Sensorineural hearing loss associated with Kawasaki disease. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October 1991.
20. Hsu H, Kunches L, Moye J, Ng P, Shea B, Tobin S, McIntosh K, **Meissner HC**, Pasternack M, Pelton S, Stechenberg B, Sullivan J: Serious cytomegalovirus disease in human immunodeficiency virus-infected children. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October 1991.
21. **Meissner HC**, Fulton DR, Hemming VG, Geggel R, Marx G, Hougen T, Connors M, Snyderman DR: A controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus infection by use of intravenous immune globulin. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October 1991.
22. Comenzo R, Malachowski M, **Meissner C**, Fulton D, Berkman E: Immune hemolysis, disseminated intravascular coagulation and serum sickness following high dose intravenous immunoglobulin therapy for Kawasaki disease. 44th Annual Meeting of American Association of Blood Banks. Baltimore, Maryland, Transfusion 1991;31:505.
23. **Meissner C**, Marx G, Geggel R, Fulton D: A retrospective comparison of two intravenous immune globulin (IVIG) products for single dose treatment of Kawasaki disease. 4th International Kawasaki Disease Symposium, Wailea, Hawaii, December 1991.

PUBLISHED ABSTRACTS

24. Hsu H, Kunches L, Ng P, Cohen J, Caldwell B and the Massachusetts Working Group on Surveillance of HIV in Children: Primary prevention of *Pneumocystis carinii* pneumonia (PCP) in infants with HIV infection. VIII International Conference on AIDS, Amsterdam, July 1992.
25. Massaro FJ, Bungay KM, Snyderman DR, Gouveia WA, Decker EL, **Meissner HC**, Rand W: The effect of antibiotic choice on length of stay in patients with community-acquired pneumonia. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, October 1992.
26. Guerina N, **Meissner HC**, McGuire J, Hsu H, Hoff R, Grady G and the Massachusetts Toxoplasma Advisory Committee: Prospective newborn screening and treatment program for congenital Toxoplasma infection (CTI). 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, October 1992.
27. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Rodriguez WJ, **Meissner HC**, Welliver RC, Hemming VG and the RSVIG Study Group: Respiratory syncytial virus (RSV) immune globulin (IG) prevents severe lower respiratory infection (LRI) in high risk children. The American Pediatric Society and the Society for Pediatric Research, Washington, D.C., May 1993.
28. Simoes EAF, Groothuis JR, Levin MJ, Hall CB, Rodriguez WJ, **Meissner HC**, Welliver RC, Hemming VG and the RSVIG Study Group: Standard (IGIV) vs. RSV enriched (RSVIG) intravenous immune globulin for RSV immunoprophylaxis. The American Pediatric Society and the Society for Pediatric Research, Washington, D.C., May 1993.
29. Leung DYM, **Meissner HC**, Fulton DR, Kotzin BL, Schlievert PM: Identification of a novel strain of toxic shock syndrome toxin-producing *Staphylococcus aureus* in Kawasaki syndrome. American Society for Clinical Investigation, Washington, D.C., May 1993.
30. Hsu H, Cohen J, Reddington C, Mao C, DeMaria A, Caldwell B and the Massachusetts Working Group on Surveillance of HIV in Children: Identification of maternal HIV infection before delivery. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 1994.
31. Mao C, Harper M, Reddington C, Cohen J, Bachur R, Caldwell B, McIntosh K, Hsu H and the Massachusetts Working Group on Surveillance of HIV in Children: Serious pneumococcal infections (SPI) in HIV-infected children. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 1994.
32. Burns JC, Glode MP, Capparelli E, Brown JA, Newburger JW and the U.S./Canadian KS Study Group: Intravenous gamma globulin (IVIG) in the treatment of Kawasaki syndrome (KS): Are all brands equal? The American Pediatric Society and the Society for Pediatric Research, San Diego, California, May 1995.
33. Guerina NG, Ware J, Burbridge J, **Meissner HC**, Lynfield R, Hsu H, Pasternack MS, Grady GF and the Massachusetts Toxoplasma Study Group: Neurodevelopmental (ND) outcomes for infants with congenital toxoplasma infection (CT) from a newborn serologic screening and treatment program. The American Pediatric Society and the Society for Pediatric Research, San Diego, California, May 1995.
34. Leung DYM, Fulton D, **Meissner HC**, Abe J, Schlievert P, Quimby F: Superantigen hypothesis of Kawasaki syndrome. 5th International Kawasaki Disease Symposium, Fukuoka, Japan, May 1995. ICS 1093.

PUBLISHED ABSTRACTS

35. Simoes EAF, Sondheimer HM, **Meissner HC**, Welliver RC, Groothuis JR and the RSVIG Cardiac Study Group: Respiratory syncytial virus immunoglobulin as prophylaxis against respiratory syncytial virus in children with congenital heart disease. The American Pediatric Society and the Society for Pediatric Research, Washington, DC, May 1996.
36. Albany E, **Meissner HC**, Snyderman DR: Neonatal Sepsis Unlikely if Blood Cultures are Negative at 48 Hours. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, Louisiana 1996.
37. Wang V, Barnett E, Harper M, **Meissner HC**, Schmidt E, Fleischer G: Occult Meningococemia. American Academy of Pediatrics, 1997 Annual meeting, New Orleans, Louisiana.
38. Burns JC, Capparelli E, Brown JA, Newburger JW, Glode M and the US/Canadian Kawasaki Syndrome Study Group: Intravenous gamma globulin treatment and retreatment in Kawasaki syndrome. #369. Infectious Disease Society of America, 35th Annual Meeting, San Francisco, California, 1997.
39. Dougherty N, **Meissner HC**: Outcomes of Hospitalization due to RSV infection in children in a tertiary medical center. H-139. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Ontario, Canada 1997.
40. **Meissner HC**, Groothuis J, Rodriguez W, Welliver R, Hoff G, Simoes E, Gray P, Loh P, Miller A, Everitt D, Thompson K, Jorkasky D: Safety and pharmacokinetics of an intramuscular monoclonal antibody to RSV (SB209763) in infants and young children at risk for severe RSV disease. H-88. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Ontario, Canada 1997.
41. Connor EM, Impact-RSV study group. Reduction of Respiratory syncytial virus (RSV) hospitalization in children with prematurity or bronchopulmonary dysplasia using intramuscular humanized monoclonal antibody to the RSV F protein (MEDI-493, Palivizumab). #824. The American Pediatric Society and the Society for Pediatric Research, New Orleans, Louisiana, May 1998.
42. DeVincenzo JP, Malley R, Ramillo O, Dennehy P, **Meissner HC**, Gruber WC, Sanchez PJ, Jafri H, Balsley J, Carlin D, Buckingham SC, Vernacchio L, Ambrosino D: Viral concentration in upper and lower respiratory secretions from respiratory syncytial virus (RSV) infected children treated with RSV monoclonal antibody. #830. The American Pediatric Society and the Society for Pediatric Research. New Orleans, Louisiana, May 1998.
43. **Meissner HC**: Preventing varicella in the United States. #WE-SA2-2. XXII International Congress of Pediatrics. Amsterdam, Holland. August, 1998.
44. **Meissner HC**: Controversy: Kawasaki disease is caused by a staphylococcal superantigen. 6th International Kawasaki disease symposium. Waikoloa, Hawaii. February 1999.
45. Sorrentino ME, Charsha-May DE, Angert A, **Meissner HC**, Pauly T, Pedraza Pena L, Prober C, Rodriguez W, Rodriguez-Santa J, Sanchez P, Simoes E, Van Veldhuisen P. #1348. Severity of RSV LRI hospitalizations in 33 to 35 week and ≥ 36 week gestational age infants. The American Pediatric Society and the Society for Pediatric Research, Baltimore, MD, April 2001.

PUBLISHED ABSTRACTS

46. **Meissner HC**, Schlievert, Shulman ST, Mason W, Wheeler G, Myones BL, Glode MP, Ruthazer R, Gerber MA, Leung DYM. Multicenter controlled blinded study to evaluate the role of bacterial superantigens in patients with Kawasaki syndrome. #1418. The American Pediatric Society and the Society for Pediatric Research, Baltimore, MD, April 2001
47. Jafri H, Sheeran P, Devincenzo J, Buckingham S, Sanchez P, Malley R, Ambrosino D, Dennehy P, **Meissner HC**, Carlin D, Ramilo O. Impact of palivizumab therapy on dynamics of chemokine concentrations in respiratory secretions of children with severe respiratory syncytial virus disease. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, Il., December 2001
48. Belshe RB, Newman FK, Wright P, Karron R, Tollefson S, Henderson F, **Meissner C**, Madhi S, Robertson D, Loh R, Sly P, Murphy B, Tatem J, Randolph V, Hackell J, Guber W. A phase I study of the safety, viral shedding profile, and immunogenicity of a live, attenuated combination RSV/PIV3 vaccine in 6-18 month old seronegative children. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, Il., December 2001
49. **Meissner HC**. The importance of MMR vaccine in the U.S. immunization policy. 36th National Immunization Conference. Denver, Colorado. April 2002
50. **Meissner HC**. Expanding Vaccine Recommendations: Influenza and meningococcal vaccines. 38th National Immunization Conference. Nashville, TN. May 2004

Printed 6/5/2018